Loading
A phase 2 trial of carboplatin in lung cancer, run by Shanghai Allink Biotherapeutics Co., Ltd., not yet recruiting.
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. is a phase 2, randomised interventional study registered as NCT07603791 by Shanghai Allink Biotherapeutics Co., Ltd., with a registry enrolment figure of 252 participants, started 2026-06-30 and due to reach its primary completion in 2027-12-30. Interventions recorded: ALK202 for injection; Osimertinib Mesylate Tablets; Ivonescimab Injection; carboplatin injection. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: TEAEs. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.